AI's Role in Medicine Hindered by Regulatory and Clinical Trial Challenges

The cost of clinical trials per drug exceeds one billion dollars and typically spans seven years. Ruxandra Teslo highlights that in the age of AI, regulatory hurdles and the lengthy process of clinical trials will increasingly bottleneck medical advancements. Notably, more than half of big Western pharma licensing deals now involve Chinese biotechs, a significant rise from zero a decade ago. This shift reflects a broader trend in pharmaceutical R&D productivity, which has been declining since 1960, with Eroom’s Law noting a decrease in new drug approvals per dollar spent on R&D. Teslo emphasizes that faster clinical trials are crucial for biomedical innovation, citing that the FDA’s acceptance of Bone Mineral Density as a surrogate endpoint led to increased interest from big pharma in osteoporosis treatments. With the right surrogates, there is potential for a 10x reduction in the time and cost of trials. This analysis underscores the pressing need for regulatory reform to keep pace with AI advancements in medicine. For further details, see Hacker News (AI filtered).